We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

CRISPR technology may soon lead to major stock growth in genomics. CRISPR therapies target diseases with genetic editing either inside or outside the body. Beam, CRISPR Therapeutics, Caribou, and ...

CRISPR technology, targeting genetic diseases and cancer, may bring major biotech stock growth. CRISPR Therapeutics and Intellia show progress with clinical trials and big pharma partnerships.

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, ...

Along Highway 101 north of the San Francisco Airport, a break-out biotech start-up named Mammoth Biosciences co-founded by Nathan Chen's sister Janice in 2018 is fast emerging in the revolutionary ...

Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore O’Neill ...

ZUG, Switzerland and BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

CRISPR Therapeutics (NASDAQ: CRSP) is a company that can potentially help revolutionize healthcare. Its gene-editing therapies can be game changers for patients living with illnesses and conditions ...

A Swiss biotechnology company said it has used the gene-editing technology CRISPR to treat a patient with a dangerous blood disease called beta thalassemia, marking the technology’s first trial run by ...

A day after experts weighed in on the ethical concerns of CRISPR, the U.S. Patent Trial and Appeal Board (PTAB) has delivered its ruling on the high-profile patent interference case shadowing the ...